See how AbbVie Inc. and Caterpillar Inc. differ across market data and performance, so you can decide which asset best fits your strategy.
$254.49
NYSE
AbbVie Inc. is a pharmaceutical company with significant exposure to immunology through Humira, Skyrizi, and Rinvoq, and to oncology through Imbruvica and Venclexta. The company was spun off from Abbott in early 2013. Its 2020 acquisition of Allergan expanded its portfolio with additional products in aesthetics, including Botox. In 2024, AbbVie further strengthened its business through the acquisitions of Cerevel in neuroscience and ImmunoGen in oncology.
Caterpillar Inc. is the world’s leading manufacturer of construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. The company reports results across Construction Industries, Resource Industries, and Energy & Transportation, with market share nearing 20% in many product categories. Caterpillar also operates a captive finance subsidiary that helps support equipment sales. Its business has a broad global footprint, with revenue roughly balanced between the United States and international markets. The construction segment is more heavily weighted toward the domestic market, while the other divisions are more geographically diversified. An independent dealer network of more than 150 dealers runs approximately 2,800 locations, extending Caterpillar’s sales and service presence to about 190 countries.